Front Row Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Front Row Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$223	Hold	5	–	–	﹤0.01%	554
2026 Q1	$132	Hold	5	–	–	﹤0.01%	549
2025 Q4	$145	Hold	5	–	–	﹤0.01%	534
2025 Q3	$139	Hold	5	–	–	﹤0.01%	536
2025 Q2	$122	Hold	5	–	–	﹤0.01%	521
2025 Q1	$104	Hold	5	–	–	﹤0.01%	496
2024 Q4	$118	Hold	5	–	–	﹤0.01%	489
2024 Q3	$128	Hold	5	–	–	﹤0.01%	488
2024 Q2	$117	Hold	5	–	–	﹤0.01%	929
2024 Q1	$144	Buy	+5	New	+$150	﹤0.01%	912
2022 Q2	–	Sell	-10	Closed	–	–	919
2022 Q1	$0	Hold	10	–	–	﹤0.01%	929
2021 Q4	$1K	Hold	10	–	–	﹤0.01%	903
2021 Q3	$1K	Hold	10	–	–	﹤0.01%	899
2021 Q2	$1K	Hold	10	–	–	﹤0.01%	903
2021 Q1	$1K	Buy	+10	New	+$992	﹤0.01%	899

Other funds holding ARKG

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Front Row Advisors's ARKG Position: Q2 2026 in Review

Front Row Advisors held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 5 shares worth $223. The position accounts for ﹤0.01% of the portfolio, ranked #554.

Front Row Advisors first reported a position in ARKG in Q1 2021 and has held it in 15 quarters since. The position peaked at $1K in Q4 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

Front Row Advisors held 5 shares of ARK Genomic Revolution ETF worth $223 as of Q2 2026.
Front Row Advisors left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
ARK Genomic Revolution ETF made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #554 holding.
Front Row Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2021 and has held it in 15 quarters since.
Front Row Advisors's ARK Genomic Revolution ETF position peaked at $1K in Q4 2021.
271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.